Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo

  • J. Neyts
  • F. Stals
  • C. Bruggeman
  • E. De Clercq
Article

Abstract

9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), a potent inhibitor of human immunodeficiency virus (HIV) replication, was evaluated for its activity against human cytomegalovirus (HCMV) in vitro, and murine cytomegalovirus (MCMV) and rat CMV (RCMV) in vivo. PMEDAP strongly inhibited HCMV-induced cytopathicity in human embryonic lung (HEL) cell cultures (EC50 3.1 µM) and caused a concentration-dependent suppression of viral DNA synthesis (IC50 5.6 µM). PMEDAP had no effect on the expression of HCMV-specific immediate early antigens (IEA) as measured on day 1 post-infection, but inhibited the expression of HCMV late antigens as measured on day 6 post-infection (EC50 5.8 µM). The diphosphate derivative of PMEDAP (PMEDAPpp) selectively inhibited HCMV-induced DNA polymerase (IC50 0.1 µM). PMEDAP proved markedly effective in reducing the mortality rate of NMRI mice that had been infected intraperitoneally or intracerebrally with a lethal dose of MCMV. PMEDAP exhibited greater anti-MCMV activity when administered as a single dose immediately after infection than when this dose was divided over repeated administrations. 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) also prevented MCMV-induced mortality, but only at a dose tenfold higher than that of PMEDAP. PMEDAP also delayed death in severe combined immune deficiency (SCID) mice that had been infected with MCMV. The effect of PMEDAP on RCMV infections in rats was less pronounced.

Keywords

Human Immunodeficiency Virus Diphosphate Lethal Dose Repeated Administration Human Cytomegalovirus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubin RH Impact of cytomegalovirus infection on organ transplant recipients. Reviews of Infectious Diseases 1990, 12, Supplement 7: 754–766.PubMedGoogle Scholar
  2. 2.
    Tyms AS, Taylor DL, Parkin JM Cytomegalovirus and the acquired immunodeficiency syndrome. Journal of Antimicrobial Chemotherapy 1989, 23, Supplement A: 89–105.Google Scholar
  3. 3.
    Stagno S, Pass RF, Dworksy ME, Henderson RE, Moore EG, Walton PD, Alford CD Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infections. New England Journal of Medicine 1982, 306: 945–949.PubMedGoogle Scholar
  4. 4.
    Britt W, Pass R, Stagno S, Alford C Pediatric cytomegalovirus infection. Transplantation Proceedings 1991, 23, Supplement 3: 115–117.PubMedGoogle Scholar
  5. 5.
    Fowler KB, Pass RF Sexually transmitted disease in mothers with congenital infection. Journal of Infectious Diseases 1991, 164: 259–264.PubMedGoogle Scholar
  6. 6.
    Verheyden JPH Evolution of therapy for cytomegalovirus infection. Reviews of Infectious Diseases 1988, 10: Supplement 3: 5477–5489.Google Scholar
  7. 7.
    Faulds D, Heel RC Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990, 39: 597–638.PubMedGoogle Scholar
  8. 8.
    Emanuel D Treatment of cytomegalovirus disease. Seminars in Hematology 1990, 27, Supplement 1: 22–27.PubMedGoogle Scholar
  9. 9.
    Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC Progressive disease due to ganciclovirresistant cytomegalovirus in immunocompromised patients. New England Journal of Medicine 1989, 320: 289–293.PubMedGoogle Scholar
  10. 10.
    Knox K, Dobryski W, Carrigan D Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991, 337: 1292–1293.Google Scholar
  11. 11.
    Drew WL, Miner RC, Busch DF, Follansbee SE, Gullet J, Mehalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC, De Armond B Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. Journal of Infectious Diseases 1991, 163: 716–719.PubMedGoogle Scholar
  12. 12.
    Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 1991, 35: 2191–2197.PubMedGoogle Scholar
  13. 13.
    De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC A novel selective broadspectrum anti-DNA virus agent. Nature 1986, 323: 464–467.PubMedGoogle Scholar
  14. 14.
    De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Research 1987, 8: 261–272.PubMedGoogle Scholar
  15. 15.
    Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 1988, 32: 1839–1844.PubMedGoogle Scholar
  16. 16.
    Neyts J, Snoeck R, Schols D, Balzarini J, De Clercq E Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3)-hydroxy-2-phosphonyl-methoxypropyl)-cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine (DHPG). Virology 1990, 179: 41–50.PubMedGoogle Scholar
  17. 17.
    Neyts J, Snoeck R, Balzarini J, De Clercq E Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) in vitro. Antiviral Research 1991, 16: 41–52.PubMedGoogle Scholar
  18. 18.
    Kern ER Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplantation Proceedings 1991, Supplement 3, 23: 152–155.Google Scholar
  19. 19.
    Neyts J, Balzarini J, Naesens L, De Clercq E Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology 1992, 37: 67–71.PubMedGoogle Scholar
  20. 20.
    Neyts J, Sobis H, Snoeck R, Vandeputte M, De Clercq E Efficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 269–279.Google Scholar
  21. 21.
    De Clercq E, Holy A Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine in various models of herpes simplex virus infection in mice. Antimicrobial Agents and Chemotherapy 1991, 35: 701–706.PubMedGoogle Scholar
  22. 22.
    Maudgal PC, De Clercq E (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. Investigative Opthalmology and Visual Science 1991, 32: 1816–1820.Google Scholar
  23. 23.
    Soike KF, Huang JL, Zhang JE, Hitchcock HJM Martin JC Evaluation of infrequent dosing regimens with (S)-1-[(3-hydroxy-2-phosphonylmethoxypropyl]-cytosine (HPMPC) on Simian varicella infection in monkeys. Antiviral Research 1991, 16: 17–28.PubMedGoogle Scholar
  24. 24.
    Stals FS, De Clercq, E Bruggeman CA Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine (DHPG) against rat cytomegalovirus infection in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1991, 35: 2262–2266.PubMedGoogle Scholar
  25. 25.
    Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A, De Clercq E Phosphonylmethoxyethyl purine derivatives, a new class of antihuman immunodeficiency virus agents. Antimicrobial Agents and Chemotherapy 1988, 32: 1025–1030.PubMedGoogle Scholar
  26. 26.
    Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, Baba M, Johns DG, De Clercq E Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)-adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences of the USA 1989, 86: 332–336.PubMedGoogle Scholar
  27. 27.
    Balzarini J, Naesens L, De Clercq E Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) in vivo increases when it is less frequently administered. International Journal of Cancer 1990, 46: 337–340.Google Scholar
  28. 28.
    Balzarini J, Naesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holy A, Schellekens H, De Clercq E 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) effectively inhibits retrovirus replication in vitro and Simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991, 5: 21–28.PubMedGoogle Scholar
  29. 29.
    Hoover EA, Ebner JP, Zeidner NS, Mullins JI Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)-adenine (PMEA). Antiviral Research 1991, 16: 77–92.PubMedGoogle Scholar
  30. 30.
    Naesens L, Balzarini J, Rosenberg I, Holy A, De Clercq E 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 1043–1047.Google Scholar
  31. 31.
    Naesens L, Balzarini J, De Celrcq E Single-dose administration of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Research 1991, 16: 53–64.PubMedGoogle Scholar
  32. 32.
    Egberinck H, Borst M, Niphuis H, Balzarini J, Neu H, Schellekens H, De Clercq E, Horzinek M, Koolen M Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)-adenine. Proceedings of the National Academy of Sciences of the USA 1990, 87: 3087–3091.PubMedGoogle Scholar
  33. 33.
    Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel HK 9-(2-phosphonylmethoxyethyl)-adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrobial Agents and Chemotherapy 1989, 33: 1864–1868.PubMedGoogle Scholar
  34. 34.
    Lin JC, De Clercq E, Pagano JS Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytos ine, on Epstein-Barr virus replication. Antimicrobial Agents and Chemotherapy 1991, 35: 2440–2443.PubMedGoogle Scholar
  35. 35.
    De Clercq E, Holy A, Rosenberg I Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrobial Agents and Chemotherapy 1989, 33: 185–191.PubMedGoogle Scholar
  36. 36.
    Field H, Awan AR Effective chemotherapy of equine herpesvirus 1 by phosphonylmethoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease. Antimicrobial Agents and Chemotherapy 1990, 34: 709–717.PubMedGoogle Scholar
  37. 37.
    Naesens L, Neyts J, Balzarini J, Holy A, Rosenberg I, De Clercq E: Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. Journal of Medical Virology 1992.Google Scholar
  38. 38.
    Bruggeman CA, Meijer H, Bosman F, Van Boven CPA Isolation of cytomegalovirus-like agent from wild rats. Archives of Virology 1982, 73: 231–241.PubMedGoogle Scholar
  39. 39.
    Holy A, Rosenberg I Synthesis of 9-(2-phosphonylmethoxyethyl)-adenine and related compounds. Collection of the Czechoslovak Chemical Communications 1987, 52: 2801–2809.Google Scholar
  40. 40.
    Holy A, Rosenberg I, Dvorakova H Synthesis of N-(3-hydroxy-2-phosphonylmethoxypropyl)-derivatives of heterocyclic bases. Collection of the Czechosovak Chemical Communications 1989, 54: 2470–2501.Google Scholar
  41. 41.
    Schols D, Snocek R, Neyts J, De Clercq E Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry. Journal of Virological Methods 1989, 26: 247–254.PubMedGoogle Scholar
  42. 42.
    Huang ES Human cytomegalovirus: III: Virus-induced DNA polymerase. Journal of Virology 1975, 16: 298–310.PubMedGoogle Scholar
  43. 43.
    Foster SA, Cerny J, Cheng YC Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)-adenine. Journal of Biological Chemistry 1991, 266: 238–244.PubMedGoogle Scholar
  44. 44.
    Balzarini J, Hao Z, Herdewijn P, Johns DG, De Clercq E Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)-adenine, a potent anti-human immunodeficiency virus compound. Proceedings of the National Academy of Sciences of the USA 1991, 88: 1499–1503.PubMedGoogle Scholar
  45. 45.
    Balzarini J, Sobis H, Naesens L, Vandeputte M, De Clercq E Inhibitory effects of 9-(2-phosphonylmethoxyethyl)-adenine and 3′-azido-2′,3′-dideoxythymidine on tumor development in mice inoculated intracerebrally with Moloney murine sarcoma virus. International Journal of Cancer 1990, 45: 486–489.Google Scholar
  46. 46.
    Naesens L, Balzarini J, De Clercq E Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)-adenine. Drug Metabolism and Disposition 1992, 20: 747–752.PubMedGoogle Scholar
  47. 47.
    Yang H, Datema R Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)-propyl]-cytosine against herpes simplex virus type 2 infections in mice. Antimicrobial Agents and Chemotherapy 1991, 35: 1596–1600.PubMedGoogle Scholar
  48. 48.
    Bosma GC, Custer RP, Bosma MJ A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301: 527–530.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1993

Authors and Affiliations

  • J. Neyts
    • 1
  • F. Stals
    • 2
  • C. Bruggeman
    • 2
  • E. De Clercq
    • 1
  1. 1.Rega Institute for Medical ResearchKatholieke Universiteit LeuvenLeuvenBelgium
  2. 2.Afdeling Medische MicrobiologieAcademisch Ziekenhuis MaastrichtMaastrichtThe Netherlands

Personalised recommendations